---

Which peptide treatments are FDA-approved, which are not, and why the pharmacy matters more than the peptide

People ask me about peptides almost every day now. They have seen a video, a forum post, or a clinic menu, and they want to know if it is real. The honest answer has three parts. Some peptides are real, approved medicines that I prescribe. Most of what is sold online as “peptide therapy” is not approved and cannot legally be made for you by any pharmacy today. And the biggest danger is usually not the peptide itself. It is what else is in the vial. In two decades of practicing medicine, I have not seen a product category where the label tells you less about what you are actually injecting.

I wrote this page in plain language on purpose. If you only read one section, read the one on what goes wrong when the maker cuts corners.

First, what “approved” means

A peptide is a short chain of amino acids. Your body makes thousands of them as signals. When the FDA approves a peptide drug, it has reviewed human studies for one specific use, one specific dose range, and one specific way of making it. The factory is inspected. Every batch is tested for strength, sterility, bacterial toxins, and heavy metals before it ships. That is what you are paying for with an approved drug, even a generic one.

“Not approved” does not always mean “useless” or “dangerous.” It means nobody has proven it works and is safe in people, and nobody is checking how it is made. Those are two separate problems. The second one is the one that puts people in the hospital.

Approved peptide treatments, and what they are approved for

This is not the full list of roughly 80 approved peptide drugs. It is the part that comes up in my office. “Approved for” is the FDA-labeled use. Doctors may also prescribe an approved drug off-label for a related problem when there is a sound reason, and that is legal.

Peptide	Brand names	Approved for
Semaglutide	Ozempic, Wegovy, Rybelsus, Wegovy tablets	Type 2 diabetes; long-term weight management; lowering heart attack and stroke risk in adults with heart disease and obesity; a form of fatty liver disease (MASH)
Tirzepatide	Mounjaro, Zepbound	Type 2 diabetes; long-term weight management; obstructive sleep apnea in adults with obesity
Liraglutide	Victoza, Saxenda, generics	Type 2 diabetes; weight management
Exenatide, dulaglutide	Byetta, Bydureon, Trulicity	Type 2 diabetes
Insulin (many types)	Many	Diabetes
Tesamorelin	Egrifta	Excess belly fat caused by HIV medicines
Bremelanotide (PT-141)	Vyleesi	Low sexual desire in premenopausal women
Oxytocin	Pitocin	Starting or strengthening labor; bleeding after delivery
Teriparatide, abaloparatide	Forteo, Tymlos	Osteoporosis with high fracture risk
Leuprolide and related drugs	Lupron, Eligard, Zoladex, Firmagon	Prostate cancer, endometriosis, fibroids, early puberty
Desmopressin	DDAVP, Nocdurna	Bed-wetting, diabetes insipidus, certain bleeding disorders
Octreotide, lanreotide	Sandostatin, Somatuline	Acromegaly and certain hormone-producing tumors
Afamelanotide	Scenesse	A rare disorder that causes painful reactions to light (EPP)
Setmelanotide	Imcivree	Obesity caused by specific rare gene defects
Glatiramer	Copaxone	Multiple sclerosis
Linaclotide, plecanatide	Linzess, Trulance	Constipation-type IBS and chronic constipation
Elamipretide	Forzinity	Barth syndrome, a rare mitochondrial disease (approved 2025)

Approved once, brand discontinued, still legal to compound

Two peptides sit in a lawful middle zone. Sermorelin was an approved drug (Geref) for growth hormone testing and treatment in children. The company stopped selling it in 2008 for business reasons, not safety reasons. Because it was part of an approved drug, a licensed compounding pharmacy can still make it for a specific patient with a prescription. Gonadorelin is in the same position and is commonly used alongside testosterone therapy. These are the growth-hormone-axis and fertility peptides a legitimate clinic can actually prescribe. Human growth hormone itself and hCG are different: both are biologics, both must come from the brand manufacturer, and neither can be compounded.

One more point on the GLP-1 medicines, because it causes confusion. The shortage that allowed pharmacies to make copies of semaglutide and tirzepatide ended in 2025. Today a compounding pharmacy may only make a patient-specific version when there is a documented medical reason, and it must use the same active ingredient as the approved drug. Many of the cheap “compounded semaglutide” products sold online used salt forms the FDA has said are not the approved drug at all.

Not approved, and no pharmacy can legally make them for you today

This is the online peptide menu. None of these has FDA approval for any use. Here is where each one stands as of September 2026.

Peptide	Sold for	Where it stands
BPC-157, TB-500, KPV, MOTS-c, Semax, epitalon	Healing, gut repair, recovery, metabolism, focus, sleep, “anti-aging”	Taken off the FDA “do not compound” list in April 2026 because the people who nominated them withdrew the paperwork, not because of new safety data. An FDA advisory panel voted narrowly in their favor in July 2026, against the advice of the FDA’s own scientists. The FDA still has to write and finalize a rule, which usually takes a year or more. Until then, no pharmacy can legally compound them.
DSIP (emideltide)	Sleep	The same panel voted no.
GHK-Cu injections, LL-37, dihexa, PEG-MGF, melanotan II	Skin and hair, immunity, brain, muscle, tanning	Panel review expected by February 2027. Not legal to compound now. (GHK-Cu in a face cream is a cosmetic and is a different question.)
CJC-1295, ipamorelin, AOD-9604, GHRP-2, GHRP-6, kisspeptin-10, selank, thymosin alpha-1	Growth hormone release, fat loss, fertility, immunity, anxiety	Still on the FDA “do not compound” list for safety concerns.
Hexarelin, IGF-1 LR3, follistatin, humanin, FOXO4-DRI	Muscle, longevity	Never even nominated. Research chemicals only.
Retatrutide, CagriSema, survodutide, mazdutide	Weight loss	Real drugs in late-stage trials or under FDA review, but not approved yet. Anything sold as retatrutide today is gray market.
MK-677, 5-amino-1MQ	Growth hormone, fat loss	Not peptides at all. Not approved. Research chemicals.

I keep the full legal timeline, including what the July 2026 vote did and did not change, on my peptide therapy: what is legal and what is not page.

What “research use only” really means

Almost every unapproved peptide sold online carries the words “for research use only, not for human consumption.” People read that as fine print. It is not. It is the seller telling you, in writing, that the product was never made to be put into a person. No sterility standard. No purity standard. No limit on metals or solvents. No inspector has ever walked through the building. If the label were honest, you would not buy it. The label is there to keep the seller out of trouble, not to keep you safe.

The four places a peptide can come from

Where a vial is made matters more than what the label says is in it. There are four kinds of sources, and the oversight drops off a cliff as you go down the list.

• Brand or generic manufacturer. FDA-inspected factory. Every batch tested for strength, sterility, bacterial toxins, and metals. This is where approved drugs come from.
• 503B outsourcing facility. Registered with the FDA, held to factory-level manufacturing rules, and inspected by the FDA. Can make larger batches for clinics.
• 503A compounding pharmacy. Licensed and inspected by the state pharmacy board. Makes one prescription at a time for one named patient. Must follow sterile-compounding standards, but is not held to full factory rules and is not routinely inspected by the FDA. Most are good. Quality still varies more than people assume.
• “Research chemical” seller. No license, no standards, no inspections. Often a reseller putting a label on bulk powder from an overseas factory it has never seen.

Here is the uncomfortable part: the worst drug-contamination disaster in modern U.S. history did not come from the bottom of that list. It came from a state-licensed compounding pharmacy.

What goes wrong when the maker cuts corners

Every one of these has actually happened. None of it is theory.

• Bacteria and bloodstream infection. An injection carries whatever is in the vial straight past your skin. If the vial was not sterile, bacteria can cause an abscess at the site, a spreading skin infection, or bacteremia, which means bacteria in the blood. Bacteremia can turn into sepsis, a whole-body reaction that can shut down organs and is a medical emergency. Non-sterile product is the most likely thing to hurt a gray-market user first.
• Endotoxin, the toxin bacteria leave behind. Even if the bacteria are dead, fragments of their cell walls, called endotoxin, stay in the liquid and cause fever, chills, body aches, and a drop in blood pressure within hours of injection. In published and independent testing, roughly 8 to 15 percent of gray-market peptide vials had measurable endotoxin. The standard purity test vendors post online cannot detect it. In 2019 the FDA warned about compounded IV glutathione that caused these reactions after the bulk powder tested high for endotoxin.
• Mold and fungus. In 2012, a licensed compounding pharmacy in Massachusetts shipped steroid vials contaminated with mold. According to the CDC, 753 people in 20 states developed fungal meningitis or other infections, and 64 died. That outbreak is why Congress created the 503B category in 2013 and tightened oversight. “Licensed” is necessary. It is not the same as “safe.”
• Lead and arsenic. When forensic labs tested peptide products seized from illegal sellers, about one in four contained arsenic or lead above the limits allowed in injectable drugs. The arsenic was the inorganic form, the kind that causes cancer, at up to ten times the limit. Lead has no safe level. It builds up in bone, kidneys, and brain, and it does not leave when you stop injecting.
• Industrial solvents and particles. The same testing found leftover synthesis solvent in every sample, plus fibers, plastic, rubber, and glass flakes in some vials. These come from the chemical process and from sloppy re-bottling.
• The wrong amount. In third-party testing of roughly 6,000 samples from about 200 sellers, more than 40 percent failed basic purity or dose standards. Some vials hold half the labeled dose. Some hold double. With a GLP-1 drug, double the dose means severe vomiting, dehydration, low blood sugar, and in some cases pancreatitis.
• The wrong molecule. FDA staff reported finding products sold as “BPC-157” that contained different active molecules from one another. Sloppy synthesis can also swap or drop amino acids, which produces a peptide that looks right on the label and behaves differently in your body.
• Your immune system turning on the peptide. The FDA’s stated concern with impure peptides is immunogenicity, meaning impurities can trigger antibodies against the peptide, and sometimes against the natural version your body makes.

Counterfeits reach approved drugs too. The FDA seized thousands of counterfeit Ozempic pens from the U.S. supply in late 2023 and hundreds more in 2025. The needles were counterfeit and their sterility could not be confirmed. The lesson is the same at every level: know who made it and who checked it.

I go deeper on the contamination data and the cancer question on my peptide risks: what is actually in the vial page.

Would a licensed provider risk their license by prescribing these?

I get asked this by patients and, quietly, by other providers. Here is my honest read.

Start with the word “prescribe.” Nobody can prescribe BPC-157 in the normal sense today, because no pharmacy can legally fill that prescription. So a clinic that offers it is doing one of three things: buying “research” vials and injecting them, using a pharmacy that is breaking the rules, or pointing you to a website. Under federal law, a drug that was never approved for any use is not an “off-label” drug. It is an unapproved and, in most cases, misbranded drug. Giving it to a patient is a federal violation, and a consent form does not change that.

The state boards have started saying this out loud. In May 2026 the Alabama Board of Medical Examiners told physicians that under no circumstances may they compound, administer, or dispense a research-grade peptide to a patient. In August 2026 the Mississippi medical, nursing, and pharmacy boards issued a joint notice, and South Carolina’s medical board issued its own, saying licensed providers may not prescribe, administer, dispense, supply, or even recommend these products, and that signed waivers do not fix the problem. Reported enforcement through early 2026 includes license suspensions in Ohio tied to research-labeled vials being found on the premises, a clinic shut down with its assets frozen in Alabama, and a $300,000 settlement with the Connecticut attorney general.

Arizona. My license comes from the Arizona Naturopathic Physicians Medical Board. MDs answer to the Arizona Medical Board, DOs to the osteopathic board, and nurse practitioners to the nursing board. Arizona law lets each of those boards censure, place on probation, suspend, or revoke a license for unprofessional conduct, and that definition reaches negligence that harms a patient and conduct that could harm one. I am not aware of an Arizona notice specific to peptides yet. The boards do not need one. The federal rule already exists, and a board can act on a single complaint. If you are wondering what an NMD can and cannot prescribe in this state, I explain it on can a naturopathic doctor prescribe medication.

Insurance. Many malpractice policies exclude claims involving unapproved drugs. If something goes wrong with a research peptide, the clinic may have no coverage, which also means the patient may have no one to recover from.

So, would they lose their license? Not automatically, and not for a conversation. Boards discipline in steps, and most cases start with a complaint or a bad outcome. But the exposure is real, it is growing every month, and boards have already suspended licenses without a single injured patient, just for the vials being there. Here is the part I want you to hold onto: the provider’s risk only becomes real if someone complains or something goes wrong. Your risk is in the vial before anyone opens it. Of the two, the patient’s harm is the more certain one, because the contamination problem is not a legal theory. It has been measured.

How to tell a legitimate peptide prescription from a risky one

• It is an FDA-approved product, or one of the few peptides a pharmacy can lawfully compound. If the name is on the “not approved” table above, stop there.
• The prescriber can name the pharmacy, and it is a state-licensed 503A pharmacy or an FDA-registered 503B facility. You can look both up.
• You were evaluated first, and labs were drawn. A prescription written after a two-minute form is not an evaluation.
• The vial has a pharmacy label with your name, the drug, the strength, and a beyond-use date. Not “research use only.”
• Nothing ships before the prescription exists, and nothing is sold from a display case in the lobby.
• The price is not suspiciously low. Sterile manufacturing and batch testing cost money. A vial that costs a fraction of the licensed price skipped something.

What we do at IMP

We prescribe approved peptides where your condition and your labs support them, and we source them only through licensed pharmacies and manufacturers. GLP-1 medicines are peptide therapy, and they are working in my patients right now. Where a growth-hormone-axis peptide is appropriate, sermorelin is the lawful option. We do not sell research peptides, and we will not while they sit outside the law with no proof of safety in people. I follow the rulemaking closely. If it finishes and real safety data arrive, we will offer those compounds properly. What I will not do is get ahead of the evidence with your body.

Most people asking about peptides want something specific: a tendon that will not heal, energy that is gone, weight that will not move. Those have measurable causes. Start with what the GLP-1 medicines can actually do and what heals tendons and joints, ranked by the evidence. Our approach to the whole category is on the peptide therapy page. Protocols here are individualized, provided through our office after we have seen your labs.

Text us at 480-485-2197 to schedule, or call. Quick response, real scheduling, no phone tree.

To Health and Wellness,
Dr. Tallman

This page is educational and is not a substitute for individualized medical advice, diagnosis, or treatment. It contains no dosing information and is not legal advice. Regulatory status changes; confirm current status on the FDA’s compounding bulk substances pages. · Leer en español

---

References

Sports Medicine, 2026 — safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance.
The American Journal of Sports Medicine, 2026 — injectable peptide therapy: a primer for orthopaedic and sports medicine physicians.
JAMA, 2026 — under FDA, unapproved peptides likely to become more widely available.
Talanta, 2018 — impurity profiling of falsified polypeptide drugs: arsenic, lead, residual solvents, and particulates.
Journal of Clinical Pharmacology, 2025 — clinical pharmacology of peptides in FDA drug labeling.
U.S. Food and Drug Administration, April 2026 — 503A bulk drug substance category updates; removal of twelve peptides from Category 2.
U.S. Food and Drug Administration, July 23–24, 2026 — Pharmacy Compounding Advisory Committee meeting materials and votes.
U.S. Food and Drug Administration, 2019 — alert on endotoxin contamination in bulk L-glutathione used for compounded injections.
U.S. Food and Drug Administration, December 2023 and April 2025 — counterfeit Ozempic alerts.
Centers for Disease Control and Prevention, 2012–2013 — multistate fungal meningitis outbreak linked to contaminated compounded methylprednisolone.
Alabama Board of Medical Examiners, May 2026 — official notice on prescribing non-FDA-approved (research-grade) peptides.
Mississippi State Board of Medical Licensure, Board of Nursing, and Board of Pharmacy, August 2026 — joint statement on research-grade peptides; South Carolina Board of Medical Examiners, August 2026 — notice on research-grade peptides.
Arizona Revised Statutes, Title 32 — disciplinary authority of the Arizona Medical Board (chapter 13) and the Naturopathic Physicians Medical Board (chapter 14).